We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+3.74%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$644M
AUM Growth
+$21.5M
Cap. Flow
+$87.7M
Cap. Flow %
13.63%
Top 10 Hldgs %
53.54%
Holding
47
New
9
Increased
25
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$13.7M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
3
SRRK icon
Scholar Rock
SRRK
+$12.6M
4
GH icon
Guardant Health
GH
+$11.6M
5
ALXO icon
ALX Oncology
ALXO
+$11.2M

Top Sells

Rank Stock Value
1
GERN icon
Geron
GERN
+$34.6M
2
VRDN icon
Viridian Therapeutics
VRDN
+$10.8M
3
FOLD
Amicus Therapeutics
FOLD
+$8.47M
4
STRO icon
Sutro Biopharma
STRO
+$4.16M
5
VKTX icon
Viking Therapeutics
VKTX
+$2.03M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$133M 20.73%
7,648,268
– –
INSM icon
2
Insmed
INSM
$25.9B
$41.2M 6.41%
615,391
+84,597
+16% +$3.28M
OLMA icon
3
Olema Pharmaceuticals
OLMA
$899M
$28.7M 4.46%
2,654,867
+701,177
+36% +$7.6M
ITOS
4
DELISTED
iTeos Therapeutics
ITOS
$25.9M 4.03%
1,745,943
– –
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$9B
$25M 3.88%
557,184
+76,596
+16% +$3.54M
MDGL icon
6
Madrigal Pharmaceuticals
MDGL
$12.3B
$19.9M 3.1%
71,185
+9,786
+16% +$2.33M
IOVA icon
7
Iovance Biotherapeutics
IOVA
$3.63B
$19M 2.95%
2,366,714
+166,714
+8% +$1.79M
NTRA icon
8
Natera
NTRA
$47B
$18.9M 2.94%
174,811
+2,398
+1% +$244K
MIRM icon
9
Mirum Pharmaceuticals
MIRM
$5.94B
$16.8M 2.62%
+492,569
New +$12.9M
RARE icon
10
Ultragenyx Pharmaceutical
RARE
$2.52B
$15.6M 2.43%
380,552
+134,962
+55% +$5.76M
MLTX icon
11
MoonLake Immunotherapeutics
MLTX
$1.28B
$15.1M 2.35%
343,235
+47,185
+16% +$2M
GH icon
12
Guardant Health
GH
$21.7B
$14.4M 2.24%
+500,000
New +$11.6M
IRON icon
13
Disc Medicine
IRON
$3.07B
$13.8M 2.14%
305,658
+194,879
+176% +$6.62M
ALKS icon
14
Alkermes
ALKS
$7.95B
$13.4M 2.09%
+557,556
New +$13.7M
EWTX icon
15
Edgewise Therapeutics
EWTX
$4.64B
$13.3M 2.07%
740,661
+299,402
+68% +$5.22M
ALXO icon
16
ALX Oncology
ALXO
$277M
$13.2M 2.04%
2,180,864
+912,393
+72% +$11.2M
MORF
17
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$12.6M 1.96%
369,384
+44,051
+14% +$1.3M
LNTH icon
18
Lantheus
LNTH
$6.58B
$12M 1.87%
+150,000
New +$11M
RVMD icon
19
Revolution Medicines
RVMD
$44.6B
$11.2M 1.75%
289,396
+16,179
+6% +$605K
AVDL
20
DELISTED
Avadel Pharmaceuticals
AVDL
$11M 1.71%
783,242
-87,907
-10% -$1.43M
XERS icon
21
Xeris Biopharma Holdings
XERS
$1.55B
$10.9M 1.69%
4,830,526
+664,030
+16% +$1.34M
AXSM icon
22
Axsome Therapeutics
AXSM
$10.4B
$10.7M 1.66%
132,312
+18,185
+16% +$1.35M
KALV
23
DELISTED
KalVista Pharmaceuticals
KALV
$10.4M 1.61%
881,937
+121,215
+16% +$1.41M
NTLA icon
24
Intellia Therapeutics
NTLA
$1.8B
$9.93M 1.54%
443,503
+10,905
+3% +$260K
HLVX
25
DELISTED
HilleVax
HLVX
$9.33M 1.45%
+645,085
New +$8.86M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q2 2024 Portfolio in Review

As of Q2 2024, MPM BioImpact held 47 positions worth $644M, up 3.5% from $622M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

MPM BioImpact deployed $87.7M of net new capital in Q2 2024, opening 9 new positions and adding to 25 existing holdings. Its largest new stake was Alkermes: 557,556 shares worth $13.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Sutro Biopharma, an estimated $4.16M trimmed.

  • MPM BioImpact's largest Q2 2024 buy was Alkermes: 557,556 shares worth $13.4M.
  • MPM BioImpact added most to ALX Oncology in Q2 2024, an estimated $11.2M increase.
  • MPM BioImpact's biggest Q2 2024 reduction was Sutro Biopharma, cutting an estimated $4.16M.
  • MPM BioImpact fully exited Geron in Q2 2024, selling an estimated $34.6M.
  • MPM BioImpact's ten largest holdings make up 54% of its $644M portfolio in Q2 2024.
  • MPM BioImpact opened 9 new positions and closed 3 in Q2 2024.
  • MPM BioImpact's portfolio value rose 3.5% quarter-over-quarter to $644M.

Based on MPM BioImpact's 13F filing for Q2 2024, filed 14 Aug 2024.